Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$1.85M$1.85M+72.7% vs Q2 2016 Net Income-$10.09M-$10.09MN/M vs Q2 2016 EPS Diluted-$0.23-$0.23N/M vs Q2 2016 Operating Income-$7,891,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,185,000N/M Margins · derivedOperating margin-425.8%+114.3 pt vs Q2 2016
Net margin-544.3%+4.1 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 11, 2017 · 42 d after period end